Madhu Sudhana Saddala

Dr. Madhu Sudhana Saddala

University of Missouri School of Medicine - Columbia
orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 July 2019 in Journal of Translational Medicine
Verified
Journal Article
Open access
PDF file
Madhu Sudhana SaddalaMadhu Sudhana Saddala
Madhu Sudhana Saddala
HHHu Huang
Hu Huang
Tumor necrosis factor α (TNFα) is a multifunctional cytokine with a potent pro-inflammatory effect. It is a validated therapeutic target molecule for several disorders related to autoimmunity and inflammation. TNFα–TNF receptor-1 (TNFR1) signaling contributes to the pathological processes of these disorders. The current study is focused on finding novel small molecules that can directly bind to TNFα and/or TNFR1, preventing the interaction between TNFα or TNFR1, and regulating downstream signaling pathways. Cheminformatics pipeline (pharmacophore modeling, virtual screening, molecular docking and in silico ADMET analysis) was used to screen for novel TNFα and TNFR1 inhibitors in the Zinc database. The pharmacophore-based models were generated to screen for the best drug like compounds in the Zinc database. The 39, 37 and 45 best hit molecules were mapped with the core pharmacophore features of TNFα, TNFR1, and the TNFα–TNFR1 complex respectively. They were further evaluated by molecular docking, protein–ligand interactions and in silico ADMET studies. The molecular docking analysis revealed the binding energies of TNFα, TNFR1 and the TNFα–TNFR1 complex, the basis of which was used to select the top five best binding energy compounds. Furthermore, in silico ADMET studies clearly revealed that all 15 compounds (ZINC09609430, ZINC49467549, ZINC13113075, ZINC39907639, ZINC25251930, ZINC02968981, ZINC09544246, ZINC58047088, ZINC72021182, ZINC08704414, ZINC05462670, ZINC35681945, ZINC23553920, ZINC05328058, and ZINC17206695) satisfied the Lipinski rule of five and had no toxicity. The new selective TNFα, TNFR1 and TNFα–TNFR1 complex inhibitors can serve as anti-inflammatory agents and are promising candidates for further research.

1 June 2019 in Gene
Verified
Journal Article
Closed access
VMVidya Mukund
Vidya Mukund
Madhu Sudhana SaddalaMadhu Sudhana Saddala
Madhu Sudhana Saddala
BFBatoul Farran
Batoul Farran
MMMastan Mannavarapu
Mastan Mannavarapu
AAAfroz Alam
Afroz Alam
PGPurnachandra N Ganji
Purnachandra N Ganji

17 February 2016 in Medicinal Chemistry Research
Verified
Journal Article
Closed access
PDF file
SDSubba Rao Devineni
Subba Rao Devineni
MGMadhava Golla
Madhava Golla
NCNaga Raju Chamarthi
Naga Raju Chamarthi
BMBalaji Meriga
Balaji Meriga
Madhu Sudhana SaddalaMadhu Sudhana Saddala
Madhu Sudhana Saddala
UAUsha Rani Asupathri
Usha Rani Asupathri

20 March 2019 in Human Genomics
Verified
Journal Article
Open access
PDF file
Madhu Sudhana SaddalaMadhu Sudhana Saddala
Madhu Sudhana Saddala
Anton LennikovAnton Lennikov
Anton Lennikov
AMAnthony Mukwaya
Anthony Mukwaya
LFLijuan Fan
Lijuan Fan
ZHZhengmao Hu
Zhengmao Hu
HHHu Huang
Hu Huang
Age-related macular degeneration (AMD) is the most common, progressive, and polygenic cause of irreversible visual impairment in the world. The molecular pathogenesis of the primary events of AMD is poorly understood. We have investigated a transcriptome-wide analysis of differential gene expression, single-nucleotide polymorphisms (SNPs), indels, and simple sequence repeats (SSRs) in datasets of the human peripheral retina and RPE-choroid-sclera control and AMD. Adaptors and unbiased components were removed and checked to ensure the quality of the data sets. Molecular function, biological process, cellular component, and pathway analyses were performed on differentially expressed genes. Analysis of the gene expression datasets identified 5011 upregulated genes, 11,800 downregulated genes, 42,016 SNPs, 1141 indels, and 6668 SRRs between healthy controls and AMD donor material. Enrichment categories for gene ontology included chemokine activity, cytokine activity, cytokine receptor binding, immune system process, and signal transduction respectively. A functional pathways analysis identified that chemokine receptors bind chemokines, complement cascade genes, and create cytokine signaling in immune system pathway genes (p value < 0.001). Finally, allele-specific expression was found to be significant for Chemokine (C-C motif) ligand (CCL) 2, 3, 4, 13, 19, 21; C-C chemokine receptor (CCR) 1, 5; chemokine (C-X-C motif) ligand (CXCL) 9, 10, 16; C-X-C chemokine receptor type (CXCR) 6; as well as atypical chemokine receptor (ACKR) 3,4 and pro-platelet basic protein (PPBP). Our results improve our overall understanding of the chemokine receptors’ signaling pathway in AMD conditions, which may lead to potential new diagnostic and therapeutic targets.

27 March 2017 in Scientific Reports
Verified
Journal Article
Open access
PDF file
Madhu Sudhana SaddalaMadhu Sudhana Saddala
Madhu Sudhana Saddala
RKRamesh Kandimalla
Ramesh Kandimalla
PAPradeepkiran Jangampalli Adi
Pradeepkiran Jangampalli Adi
SBSainath Sri Bhashyam
Sainath Sri Bhashyam
UAUsha Rani Asupatri
Usha Rani Asupatri
The present study, we design and synthesize the novel dihydropyridine derivatives, i.e., 3 (a-e) and 5 (a-e) and evaluated, anticonvulsant activity. Initially due to the lacuna of LCC, we modeled the protein through modeller 9.15v and evaluated through servers. Docking studies were performed with the synthesized compounds and resulted two best compounds, i.e.,5a, 5eshowed the best binding energies. The activity of intracellular Ca2+measurements was performed on two cell lines: A7r5 (rat aortic smooth muscle cells) and SH-SY5Y (human neuroblastoma cells). The 5a and 5e compounds was showing the more specific activity on L-type calcium channels, i.e. A7r5 (IC50 = 0.18 ± 0.02 and 0.25 ± 0.63 μg/ml, respectively) (containing only L-type channels) than SH-SY5Y (i.e. both L-type and T-type channels) (IC50 = 8 ± 0.23 and 10 ± 0.18 μg/ml, respectively) with intracellular calcium mobility similar to amlodipine. Finally, bothin silicoandin vitroresults exploring two derivatives 5a and 5e succeeded to treat cadmium toxicity.

13 November 2018 in Scientific Reports
Verified
Journal Article
Open access
PDF file
Madhu Sudhana SaddalaMadhu Sudhana Saddala
Madhu Sudhana Saddala
Anton LennikovAnton Lennikov
Anton Lennikov
DGDennis J. Grab
Dennis J. Grab
GLGuei-Sheung Liu
Guei-Sheung Liu
STShibo Tang
Shibo Tang
HHHu Huang
Hu Huang
Placental growth factor (PlGF or PGF), a member of the vascular endothelial growth factor (VEGF) sub-family, plays a crucial role in pathological angiogenesis and inflammation. However, the underlying molecular mechanisms that PlGF mediates regarding the complications of non-proliferative diabetic retinopathy (DR) remain elusive. Using an LC-MS/MS-based label-free quantification proteomic approach we characterized the alterations in protein expression caused by PlGF ablation in the retinas obtained from C57BL6, Akita, PlGF−/− and Akita.PlGF−/− mice. After extraction and enzymatic digestion with Trypsin/LysC, the retinal proteins were analyzed by Q-Exactive hybrid Quadrupole-Orbitrap mass spectrometry. Differentially expressed proteins (DEPs) were identified in four comparisons based on Z-score normalization and reproducibility by Pearson’s correlation coefficient. The gene ontology (GO), functional pathways, and protein-protein network interaction analysis suggested that several proteins involved in insulin resistance pathways (Gnb1, Gnb2, Gnb4, Gnai2, Gnao1, Snap2, and Gngt1) were significantly down-regulated in PlGF ablated Akita diabetic mice (Akita.PlGF−/− vs. Akita) but up-regulated in Akita vs. C57 and PlGF−/− vs. C57 conditions. Two proteins involved in the antioxidant activity and neural protection pathways, Prdx6 and Map2 respectively, were up-regulated in the Akita.PlGF−/− vs. Akita condition. Overall, we predict that down-regulation of proteins essential for insulin resistance, together with the up-regulation of antioxidant and neuroprotection proteins highlight and epitomize the potential mechanisms important for future anti-PlGF therapies in the treatment of DR.